Enrolling Studies

A Randomized Multicenter Study for Isolated Skin Vasculitis (ARAMIS)

This study will compare the effectiveness of three different FDA approved drugs for the treatment of skin vasculitis, look at how participants respond to the drugs, and see if there are characteristics that predict, in the future, which patients will respond to which drugs. Participants are randomly assigned to 1 of the 3 drugs.

ClinicalTrials.gov ID: NCT02939573

Study Duration: 12 to 18 months

Disease(s): Cutaneous Polyarteritis Nodosa (cPAN), Immunoglobulin A Vasculitis (IgA), Skin Vasculitis

Efficacy and Safety of Study Drug NS-229 in Treatment of Eosinophilic Granulomatosis with Polyangiitis

The main purpose of this study is to learn if the investigational drug NS-229 is safe and effective in treating adults with EGPA that returns (relapses) or has not responded to treatment. Participants are randomly assigned to receive either NS-229 or a placebo, taken by mouth.

Participants come to the Perelman Center for 11 study visits over 9 months.

ClinicalTrials.gov ID: NCT06046222

Study Duration: 9 months

Disease(s): Eosinophilic Granulomatosis with Polyangiitis (EGPA/ Churg-Strauss)

Depemokimab Compared with Mepolizumab for Patients with EGPA on Standard of Care Therapy (OCEAN)

The purpose of this study is to learn if the investigational drug depemokimab is safe and effective compared to mepolizumab for adults with EGPA that returns (relapses) or has not responded to standard treatment. Mepolizumab is approved by the FDA to treat EGPA. Both drugs are injected under the skin.

Participants come to the Perelman Center for about 18 study visits over 1 year and 2 months.

ClinicalTrials.gov ID: NCT05263934

Study Duration: 14 months

Disease(s): Eosinophilic Granulomatosis with Polyangiitis (EGPA/ Churg-Strauss)

Clinical Transcriptomics in Systemic Vasculitis (CUTIS)

This study is being done to learn about the causes, disease process, and develop potential treatments for skin vasculitis. It is also looking at the differences between the different types of skin vasculitis. Participants with active skin vasculitis will have a skin biopsy.

ClinicalTrials.gov ID: NCT03004326

Study Duration: Participants will have 1 study visit at Penn.

Disease(s): Eosinophilic Granulomatosis with Polyangiitis (EGPA/ Churg-Strauss), Granulomatosis with Polyangiitis (GPA), Immunoglobulin A Vasculitis (IgA), Microscopic Polyangiitis (MPA), Polyarteritis Nodosa (PAN), Skin Vasculitis

Abatacept (CTLA4-Ig) in Giant Cell Arteritis (ABAGART)

The main purpose of this study is to understand how adults with a new diagnosis of GCA or those with relapsing disease respond to the investigational drug abatacept (also called Orencia). Participants are randomly assigned to receive either abatacept or a placebo. Participants self-administer a weekly subcutaneous injection of abatacept or placebo.

Participants come to the Perelman Center for 8 study visits over 18 months. If during the 18 months, participants do not respond to study treatment or have a relapse, they will have the option to start taking open-label abatacept for 18 months.

ClinicalTrials.gov ID: NCT04474847

Study Duration: Up to 18 months

Disease(s): Giant Cell Arteritis (GCA)

Nasal Microbiome in ANCA Associated Vasculitis and Relapsing Polychondritis (NMB)

The purpose of this study is to study the community of microbes living in the noses of adults with ANCA-associated vasculitis (AAV) and RP and to compare the composition of their nasal microbiome with those of healthy controls (those who do not have AAV and RP) over time and correlate disease activity.  There are no study drugs involved with this study.  Participants have nasal swabs taken and fill out questionnaires.  Study visits are combined with regular clinic visits to your rheumatologist at Penn.  The study is currently only recruiting participants with RP.

ClinicalTrials.gov ID: Not applicable

Study Duration: 2-3 years depending on whether participant has a disease relapse

Disease(s): Relapsing Polychondritis (RP)

Redefining Autoimmune Diseases Across Rheumatology (RADAR)

The goal of this study is to understand the molecular changes (tissue and cell reactions) in the immune system that happen before and during relapse/disease flares, disease progression, or responses to treatment in adults with vasculitis. If we can better understand the changes in the immune response, we may be able to understand the cause of these diseases and develop better tests and therapies. Participants have nasal swabs taken, blood and urine collected, and fill out questionnaires. Study assessments are done at your usual clinic visits with your rheumatologist at Penn.

ClinicalTrials.gov ID: Not applicable

Study Duration: Up to 2 years

Disease(s): Eosinophilic Granulomatosis with Polyangiitis (EGPA/ Churg-Strauss), Granulomatosis with Polyangiitis (GPA), Microscopic Polyangiitis (MPA)

VCRC Genetic Repository One-Time DNA Study

Clinical information from medical records and DNA blood samples collected from participants will be used to identify and study genetic markers that increase the risk of developing vasculitis.  DNA is being collected from people with various types of vasculitis. 

ClinicalTrials.gov ID: Not applicable

Study Duration: 1 blood draw at a regular rheumatology clinic visit

Disease(s): Central Nervous System Vasculitis (CNSV), Cutaneous Polyarteritis Nodosa (cPAN), Eosinophilic Granulomatosis with Polyangiitis (EGPA/ Churg-Strauss), Giant Cell Arteritis (GCA), Granulomatosis with Polyangiitis (GPA), Immunoglobulin A Vasculitis (IgA), Microscopic Polyangiitis (MPA), Polyarteritis Nodosa (PAN), Relapsing Polychondritis (RP), Skin Vasculitis, Takayasu’s Arteritis (TAK)

VCRC Longitudinal Study of Central Nervous System Vasculitis (CNSV)

The data from this research will be used by scientists to study the causes of CNSV, why certain people have CNSV, how it affects the body, and treatment strategies. There are no study drugs involved with this study. Study visits are combined with regular clinic visits to your rheumatologist at Penn.

ClinicalTrials.gov ID: Not applicable

Study Duration: Up to 3 years

Disease(s): Central Nervous System Vasculitis (CNSV)

VCRC Longitudinal Study of Eosinophilic Granulomatosis with Polyangiitis (EGPA)

This is an observational study being done to learn more about EGPA by following a large group of patients for several years. The data from this study will be used by scientists to study the causes of EGPA, understand better what patients feel with EGPA, find new ways to track disease and predict responses, and to understand how to best treat patients with EGPA. There are no study drugs involved with this study. Study visits are combined with regular visits to your rheumatologist at Penn.

ClinicalTrials.gov ID: Not applicable

Study Duration: 5 years

Disease(s): Eosinophilic Granulomatosis with Polyangiitis (EGPA/ Churg-Strauss)

VCRC Longitudinal Study of Relapsing Polychondritis (RP)

The data from this study will be used by scientists to study the causes of RP, understand better what patients feel with RP, find new ways to track symptoms and predict responses, and to understand how to best treat patients with RP. There are no study drugs involved with this study. Study visits are combined with regular clinic visits to your rheumatologist at Penn.

ClinicalTrials.gov ID: Not applicable

Study Duration: Up to 6 years

Disease(s): Relapsing Polychondritis (RP)

Vessel Wall Enhancement in Giant Cell Arteritis (VEGA)

The main purpose of this observational, longitudinal study is to see how well magnetic resonance imaging (MRI) can detect inflammation of arteries that supply blood to the head, brain, and eyes. This may be useful in the diagnosis, monitoring, and treatment of GCA. Participants have one or more MRIs at the Perelman Center.

ClinicalTrials.gov ID: NCT05865054

Study Duration: Up to 2 years depending on participant's diagnosis and initial MRI results

Disease(s): Giant Cell Arteritis (GCA)

Vasculitis Sino-Nasal Indicators for Flares (V-SNIFF)

This study aims to learn more about how symptoms in the nose and sinuses impact patients living with vasculitis and relate to relapse or flare of vasculitis. Participants fill out questionnaires online about themselves and their health every 3 months. There are no in-person study visits.

Please visit the Vasculitis Patient-Powered Research Network (VPPRN) for information about how to participate.

ClinicalTrials.gov ID: Not applicable

Study Duration: Up to 2 years

Disease(s): Eosinophilic Granulomatosis with Polyangiitis (EGPA/ Churg-Strauss), Granulomatosis with Polyangiitis (GPA), Microscopic Polyangiitis (MPA)

A Pragmatic, Open-Label, Two-Stage, Pilot Study of Effectiveness of Immunomodulatory Medications for Patients with Relapsing Polychondritis (PROSPECT)

The purpose of this study is to understand the effectiveness of commonly used medications for treating RP in adults with mild to moderately active RP. Participants have regular clinic visits and assessments with their rheumatologist such as physical exams and bloodwork. Questionnaires are done for research purposes.

There are 2 stages of the study - each involving up to 4 in-person visits over 6 months. Participants come to the Perelman Center or Penn Medicine University City (PMUC). Visits are also done by video or phone. If during the 6 months, participants do not respond to study treatment or have a relapse, they will have the option enter stage 2 of the study and start a new medicine.

ClinicalTrials.gov ID: NCT06941376

Study Duration: 6 to 12 months

Disease(s): Relapsing Polychondritis (RP)